BridgeMD
Prevention study for Pancreatic Diseases
Official title Evaluating the Safety and Efficacy of Ondansetron in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis
ClinicalTrials.gov ID: NCT06861010
What this study is testing
What is Ondansetron?
Ondansetron is an investigational medicine, being studied as a potential treatment for pancreatic diseases.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Endoscopic retrograde cholangiopancreatography (ERCP (, a key tool that is used in diagnosis and treatment of pancreato-biliary diseases. Post-ERCP pancreatitis (PEP) is the most common and serious complication that can occur following this procedure and can lead to significant morbidity and mortality.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Age more than 18 years old.
- Gender: Males and Females
- Patients with suitable indications for ERCP due to suspected pancreato-biliary disorders.
- Blood amylase and lipase levels before ERCP are within the normal limits.
You likely can't join if
- Age of less than18 years.
- Uncontrolled diabetes mellitus (DM)
- Severe bleeding tendency
- Impaired renal function (serum creatinine \> 2 mg/dL), (creatinine clearance \<30 ml/min)
- Patients with severe heart disease.
- people who underwent prior biliary or pancreatic sphincterotomy or dilatation or stenting of either duct.
See the full eligibility criteria
- Age more than 18 years old.
- Gender: Males and Females
- Patients with suitable indications for ERCP due to suspected pancreato-biliary disorders.
- Blood amylase and lipase levels before ERCP are within the normal limits.
- Age of less than18 years.
- Uncontrolled diabetes mellitus (DM)
- Severe bleeding tendency
- Impaired renal function (serum creatinine \> 2 mg/dL), (creatinine clearance \<30 ml/min)
- Patients with severe heart disease.
- people who underwent prior biliary or pancreatic sphincterotomy or dilatation or stenting of either duct.
- Currently pregnant or nursing
- Admission due to established pancreatitis before ECRP
- Unwillingness to undergo ERCP.
- Previously documented allergy to ondansetron.
The study team makes the final eligibility decision.
Where it's taking place
- Tanta, Egypt
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tanta, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.